Merck stops development of BTK inhibitor nemtabrutinib after Phase 3 risk‑benefit review
Merck announced that it is ending the BELLWAVE clinical program for nemtabrutinib, an oral BTK inhibitor, after an external data monitoring committee concluded that the drug’s benefits may not outweigh its risks in the Phase 3 BELLWAVE‑011 trial. The company also halted the two other late‑stage studies, BELLWAVE‑008 and BELLWAVE‑010, and will inform investigators and patients while continuing to analyze the data. The decision was confirmed by Merck’s senior oncology leader, Dr. Marjorie Green.
Why it matters
The termination removes a potential new therapy from Merck’s hematology pipeline, reducing near‑term growth prospects in blood‑cancer treatments. Investors should adjust expectations for future revenue from BTK inhibitors and focus on the company’s remaining pipeline candidates.
Key facts
- 1Merck discontinued the Phase 3 BELLWAVE‑011 trial (NCT06136559) after an external Data Monitoring Committee suggested the benefits may not outweigh the risks. merck.com
- 2The company also ended the broader BELLWAVE program, including Phase 3 studies BELLWAVE‑008 and BELLWAVE‑010. merck.com
- 3Nemtabrutinib (MK‑1026) is an investigational oral, non‑covalent BTK inhibitor being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other hematologic malignancies. merck.com
- 4Dr. Marjorie Green, who leads global oncology clinical development as senior vice president at Merck, said the company will continue to pursue solutions for patients with blood cancers. merck.com
- 5Merck’s stock closed at $143.37, down 0.75%, following the announcement. rttnews.com
- 6The drug was acquired as part of Merck’s $2.7 billion purchase of ArQule. biospace.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.